Peptide comparison · research use only
BPC-157 vs TB-500: two different molecules, one honest comparison.
BPC-157 and TB-500 are the two peptides people compare — and combine into the so-called 'Wolverine stack' — but they are genuinely different molecules studied along different pathways, and the honest answer to 'which is better' is that there is no head-to-head human trial to declare a winner. BPC-157 is a synthetic pentadecapeptide, 15 amino acids, corresponding to a partial sequence of a protein found in human gastric juice; it is examined in animal models in angiogenesis, gut and tendon research contexts. TB-500 is a synthetic peptide fragment corresponding to the actin-binding region of thymosin beta-4, a naturally occurring 43-amino-acid protein; it is studied for actin regulation and cell migration in research models. They also differ in how long each persists and the cadence used in research protocols. This page lays the two side by side as a research reference so the distinction is clear. Both are research-use-only compounds, not approved drugs — nothing here is a dosing schedule, an efficacy claim, or medical advice.
BPC-157 — the gastric-juice pentadecapeptide
BPC-157 is a stable synthetic 15-amino-acid peptide derived from a partial sequence of 'body protection compound', a protein identified in human gastric juice. In animal-model research it is associated with angiogenic (blood-vessel) and gut/tendon contexts, and it is notable for being studied via both oral and injectable routes because of its relative stability in gastric conditions. It is a research compound — no human-use or efficacy claim is made here.
BPC-157 dosage reference →TB-500 — the thymosin beta-4 fragment
TB-500 is a synthetic peptide corresponding to the actin-binding region (the LKKTETQ domain) of thymosin beta-4, a naturally occurring 43-amino-acid protein present in many tissues. In research models it is studied for actin regulation and cell migration, and it is described as acting more systemically than a locally-applied compound. As with BPC-157, this is preclinical research framing, not a statement about human outcomes.
TB-500 dosage reference →The half-life difference that changes cadence
The two behave differently in time. BPC-157's systemic plasma presence is short (reported under ~30 minutes) even though tissue-level effects in studies are described as outlasting that window. TB-500 / thymosin beta-4 fragment is described with a longer tissue persistence, which is why research protocols for it commonly use a twice-weekly cadence rather than daily. Mixing up 'plasma half-life' and 'how long the effect is studied to last' is the most common confusion — they are not the same number.
TB-500 half-life →Why they get stacked (the "Wolverine stack")
Because the two are studied along different mechanisms, communities frame them as 'complementary' and combine them — the pairing nicknamed the 'Wolverine stack'. Be precise about the limit: complementary mechanisms in rodent studies is not proven synergy in humans, and there is no large human trial of the combination. The comparison and the stack are two sides of the same honest point — these are distinct research tools, not interchangeable, and not proven together in people.
The Wolverine stack →"Which is better?" — why that's the wrong question
There is no evidence-based 'winner'. No head-to-head human trial compares BPC-157 and TB-500 for any outcome, so a ranking would be invented. The useful framing is that they are different molecules with different research mechanisms and different persistence — which is why they are compared AND combined, not why one replaces the other. Anyone claiming one is definitively superior for a human result is going past the evidence.
How they're combined →The verification point applies to both
Each peptide is defined by its exact sequence, and a truncated or mis-synthesised chain can pass a bare HPLC purity number while being the wrong molecule — in which case none of the research above transfers to that vial. That is why identity by mass spectrometry, matched to the specific lot, is the real test, not a headline purity percentage. Titan supplies both BPC-157 and TB-500 with lot-matched, in-house release documentation (HPLC + ESI-MS identity) available on request.
Lot COA checklist →The detail, in plain terms
The distinctions that actually matter.
Reproduced as a research reference. Both are research-use-only compounds; nothing here is a dosing schedule, an efficacy claim, or medical advice. Human evidence for either — and for the combination — is limited and early.
- Different molecules
- BPC-157 is a 15-amino-acid pentadecapeptide; TB-500 is a thymosin beta-4 fragment. Not variants of one compound.
- Different origins
- BPC-157 from a gastric-juice protein sequence; TB-500 from a naturally occurring 43-amino-acid protein present in many tissues.
- Different research mechanisms
- BPC-157: angiogenesis/gut/tendon animal-model research; TB-500: actin regulation and cell migration.
- Different time profiles
- BPC-157 short systemic plasma presence; TB-500 longer tissue persistence — which is why cadences differ in research protocols.
- No head-to-head human trial
- There is no study ranking one above the other for a human outcome; 'which is better' has no evidence-based answer.
- Why they're compared AND stacked
- Distinct mechanisms → studied separately and combined (the 'Wolverine stack'), but combination synergy in humans is not proven.
- Verification applies to both
- Sequence-defined molecules; identity by mass spec matched to the lot is the real check, not a bare purity %.
- What Titan stocks
- Both, as separate RUO research materials with lot-matched in-house release sheets (HPLC + ESI-MS) on request.
Side by side
BPC-157 vs TB-500, at a glance.
A research-reference comparison of the two peptides — chemistry and studied contexts, not efficacy claims. There is no head-to-head human trial, so nothing below ranks one above the other for any human outcome.
| Criteria | BPC-157 | TB-500 |
|---|---|---|
| Molecule type | Synthetic pentadecapeptide (15 amino acids) | Synthetic fragment of thymosin beta-4's actin-binding region |
| Origin | Partial sequence of a protein in human gastric juice | Fragment of a naturally occurring 43-amino-acid protein |
| Primary research context | Angiogenesis, gut and tendon research (animal models) | Actin regulation and cell migration (research models) |
| Action framing | Studied with local and systemic effects; oral + injectable routes | Described as acting more systemically |
| Time profile | Short systemic plasma presence (<~30 min); tissue effect studied to outlast it | Longer tissue persistence |
| Typical research cadence | Often studied daily in protocols | Often twice-weekly in protocols |
| Human trial evidence | Limited / early | Limited / early |
| Titan SKU | BPC-157 vial — $54.99 (RUO) | TB-500 vial — $89.99 (RUO) |
Questions researchers ask
Before you order.
- What is the difference between BPC-157 and TB-500?
- They are two different molecules. BPC-157 is a synthetic 15-amino-acid pentadecapeptide derived from a partial sequence of a protein in gastric juice, studied in animal models in angiogenesis and gut/tendon contexts. TB-500 is a synthetic fragment of the actin-binding region of thymosin beta-4 (a naturally occurring 43-amino-acid protein), studied for actin regulation and cell migration. They also differ in time profile — BPC-157 has a short systemic plasma presence while TB-500 is described with longer tissue persistence. Both are research-use-only compounds; this is a reference, not medical advice.
- Is BPC-157 or TB-500 better?
- There is no evidence-based answer, because no head-to-head human trial compares them for any outcome. They are different molecules with different research mechanisms and different persistence, which is why they are compared and often combined rather than treated as interchangeable. Any claim that one is definitively 'better' for a human result goes past the available evidence.
- Can you take BPC-157 and TB-500 together?
- The pairing is exactly what communities nickname the 'Wolverine stack', and the rationale people give is that the two are studied along different (allegedly complementary) mechanisms. Honestly, though: there is no large human trial of the combination, so combined synergy in people is not proven. Titan supplies both strictly as research-use-only reagents and makes no human-use, dosing, or efficacy claims.
- Why do BPC-157 and TB-500 have different dosing cadences in research?
- Because of their time profiles. BPC-157's systemic plasma presence is short (reported under about 30 minutes), so it is often studied daily, while TB-500 / thymosin beta-4 fragment is described with longer tissue persistence, which is why research protocols for it commonly use a twice-weekly cadence. Note this describes published research cadence, not a recommendation for use.
- Are BPC-157 and TB-500 FDA-approved?
- No. Neither is an FDA-approved drug. BPC-157's regulatory status is in motion — removed from the FDA Category 2 bulks list in April 2026, with a final compounding decision pending at the July 23–24, 2026 PCAC meeting. Titan operates strictly in the research-use-only market and does not sell either for human use.